We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Tools
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| N4 Pharma Plc | LSE:N4P | London | Ordinary Share | GB00BYW8QM32 | ORD 0.4P |
| Price Change | % Change | Share Price | Shares Traded | Last Trade
|
|
|---|---|---|---|---|---|
| 0.00 | 0.0% | 0.825 | 142,000 | 07:30:05 |
| Bid Price | Offer Price | High Price | Low Price | Open Price | |
|---|---|---|---|---|---|
| 0.75 | 0.90 | 0.825 | 0.825 | 0.825 | |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Drug & Proprietary Stores | -1.03M | -0.0057 | -1.44 | 1.48M |
| Last Trade Time | Trade Type | Trade Size | Trade Price | Currency |
|---|---|---|---|---|
| 15:55:31 | O | 125,000 | 0.7666 | GBX |
| Date | Time | Source | Headline |
|---|---|---|---|
| 31/10/2023 | 07:00 | UKREG | N4 Pharma PLC Total Voting Rights |
| 09/10/2023 | 06:00 | RNSNON | N4 Pharma PLC Investor Presentation via Investor Meet Company |
| 03/10/2023 | 07:15 | UKREG | N4 Pharma PLC Holding(s) in Company |
| 02/10/2023 | 06:00 | RNSNON | N4 Pharma PLC Investor Presentation |
| 28/9/2023 | 09:20 | ALNC |  N4 Pharma shares fall as places shares to fund Nanogenics stake buy |
| 28/9/2023 | 06:00 | UKREG | N4 Pharma PLC Acquisition of Controlling Interest in Nanogenics |
| 12/9/2023 | 12:43 | ALNC | N4 Pharma interim loss narrows slightly as business outreach ongoing |
| 12/9/2023 | 06:00 | UKREG | N4 Pharma PLC Interim Results |
| 25/7/2023 | 09:12 | ALNC | N4 Pharma shares soar on further patent grant for Nuvec in US |
| 25/7/2023 | 06:00 | UKREG | N4 Pharma PLC Patent Grant and Board Change |
N4 Pharma (N4P) Share Charts1 Year N4 Pharma Chart |
|
1 Month N4 Pharma Chart |
Intraday N4 Pharma Chart |
| Date | Time | Title | Posts |
|---|---|---|---|
| 14/11/2023 | 10:53 | N4 Pharma | 3,922 |
| 20/5/2021 | 07:25 | N4 Pharma - Making good drugs better. | 4,391 |
| 14/9/2020 | 06:40 | N4P Covid-19 Wealth Warning | 108 |
| Trade Time | Trade Price | Trade Size | Trade Value | Trade Type |
|---|---|---|---|---|
| 2023-11-28 15:55:32 | 0.77 | 125,000 | 958.25 | O |
| 2023-11-28 12:11:07 | 0.78 | 17,000 | 132.18 | O |
| Top Posts |
|---|
Posted at 28/11/2023 08:20 by N4 Pharma Daily Update N4 Pharma Plc is listed in the Drug & Proprietary Stores sector of the London Stock Exchange with ticker N4P. The last closing price for N4 Pharma was 0.83p.N4 Pharma currently has 181,080,349 shares in issue. The market capitalisation of N4 Pharma is £1,484,859. N4 Pharma has a price to earnings ratio (PE ratio) of -1.44. This morning N4P shares opened at 0.83p |
Posted at 28/9/2023 09:36 by bingham Not for the share price it seems. |
Posted at 25/7/2023 07:13 by tomboyb 25/07/2023 7:00amUK Regulatory (RNS & others) N4 Pharma (LSE:N4P) Intraday Stock Chart Tuesday 25 July 2023 Click Here for more N4 Pharma Charts. TIDMN4P RNS Number : 0209H N4 Pharma PLC 25 July 2023 25 July 2023 N4 Pharma Plc ("N4 Pharma" or the "Company") Patent Grant and Board Change N4 Pharma Plc (AIM: N4P), the specialist pharmaceutical company developing Nuvec(R), a novel delivery system for cancer treatments and vaccines, announces two operational updates. Granting of further US patent The University of Queensland has informed the Company that it has been notified by the US patent attorney of the granting of its further patent application in relation to Nuvec(R) in the United States. N4 Pharma has licensed the exclusive worldwide rights to Nuvec(R) from the University of Queensland for therapeutic uses in humans and animals. This granted patent in the US is for the composition of matter of the nanoparticle itself and will sit alongside the first US patent grant announced on 31 January 2022, which concerned how the nanoparticle is made using a broad description of the manufacturing process used by the Company. Board Change The Company announces that John Chiplin, currently Non-Executive Chairman, is retiring from the Board for personal reasons. Chris Britten, currently a Non-Executive Director of the Company, will assume the role of Non-Executive Chairman of N4 Pharma with effect from 1 August 2023. The Company will initiate a search process to identify an additional Non-Executive Director and will provide an update as and when appropriate. Nigel Theobald, Chief Executive Officer of the Company, commented: " We are delighted to receive notification of this further patent grant for our licensed patent in this critical and influential market. "The granting of this patent now means the patents in the US are on equal terms to those granted in other territories for both the particle itself and how it is made. "On behalf of the Board, I would like to thank John f |
Posted at 25/7/2023 07:04 by earwacks USA patent news update is very welcome strengthening of intellectual property. Research in America is funded a thousand times more in this area. So when does the money runnout? That is the beauty of N4, there are no expensive lab costs they license or lend at the moment the nano technology to the drug companies. At some stage it will become an industry standard in the treatment of cancers and delivery of vaccinations. Looks like we are still ahead of the game in this area and the professor at Queens uni in Australia who are partners has been awarded a grant to further research at no cost to N4p. The hard miles have been done in establishing the technology property and establishing up to date world wide patents. |
Posted at 25/4/2023 06:19 by jakleeds RNS Number : 2792XN4 Pharma PLC 25 April 2023 25 April 2023 N4 Pharma Plc ("N4 Pharma" or the "Company") siRNA update N4 Pharma Plc (AIM: N4P), the specialist pharmaceutical company developing Nuvec(R), a novel delivery system for cancer treatments and vaccines, is pleased to provide a further update on its ongoing in vitro siRNA research work. BCL-2 assay has been established Further to the announcement on 18 April 2023, the Company has now completed work on establishing assays to measure how Nuvec(R) loaded with BCL-2 siRNA can silence expression of the BCL-2 protein. BCL-2 is a form of protein that regulates cell death in healthy cells however aberrant expression can facilitate tumour development and resistance to cancer therapy. Testing underway to generate dose response curve for BCL-2 studies This means that the Company can now proceed to generate a dose response curve for knockdown of BCL-2 expression to compliment the one already generated for EGFR (epidermal growth factor receptor). EGFR is found on the surface of some normal cells and is involved in cell growth. It may also be found at high levels on some types of cancer cells, which causes these cells to grow and divide. In vitro studies indicate similar inhibition profile to two commercial therapies Further in vitro studies have demonstrated that the maximum inhibition of cell growth by SiRNA to either EGFR or BCL-2 loaded on Nuvec(R) was comparable to that produced by two commercially available small molecule drugs, Gefitinib for EGFR and Venetoclax for BCL-2. Gefitinib: (sold in Europe and Asia) is a type of targeted small molecule cancer drug called a tyrosine kinase inhibitor (TKI) . Tyrosine kinases are proteins that send signals telling cancer cells to grow. Gefitinib blocks these signals. For Gefitinib to work the cancer cells need to have receptors for EGFR. Venetoclax: sold under the brand names Venclexta and Venclyxto, is a type of targeted therapy drug called a BCL-2 inhibitor (blocker)used to treat adults with chronic lymphocytic leukaemia, small lymphocytic lymphoma, or acute myeloid leukaemia. Some leukaemia or cancer cells make too much of the BCL-2 protein. Next steps Further work is planned to assess the minimal loading of siRNA on Nuvec(R) to achieve comparable inhibition to the two commercially available drugs. The next step in the in vitro research work is to undertake a full dose response curve study for siRNA loaded Nuvec(R) and compare to the dose response curve for Gefitinib and Venetoclax. Nigel Theobald, Chief Executive Officer of the Company, commented: "We are very pleased with these in vitro results for Nuvec(R) loaded with EGFR and BCL-2, which show that the first investigated dose produces comparable cellular apoptosis to two commercially available products. "We also now have the assay established to complete the dose response expression work for BCL-2, but we already know that BCL-2 must be expressed, as the cell apoptosis work has shown that it knocks down the gene to produce cell death." |
Posted at 18/11/2022 09:53 by goforgold1 Fuvking hell Turner Pope . The cowboys of AIM . This share is doomed it's either TP or Death Spiral Loan . Wow Another con full of them at moment . Never buy a share from were TP involved your lose everything |
Posted at 18/11/2022 09:48 by nobbygnome Wow, bid below the placing price! |
Posted at 18/11/2022 07:15 by nobbygnome Ouch. Further massive dilution at a very low price! |
Posted at 01/11/2022 12:45 by ch1rp I think N4P know a little bit more than you Nobbs. After all you have been shorting here for years. |
Posted at 04/10/2022 06:16 by jakleeds Looks very promising4 October 2022 N4 Pharma Plc ("N4 Pharma" or the "Company") Double siRNA Testing Update N4 Pharma Plc (AIM: N4P), the specialist pharmaceutical company developing Nuvec(R) , a novel delivery system for cancer treatments and vaccines, is pleased to announce successful in vitro testing of Nuvec(R) loaded with two small interfering RNA (siRNA) probes. On 14 September 2022, the Company announced a strategic update highlighting its intention to focus its further development work on multiple loaded siRNA on Nuvec(R) . T he Company has now completed initial in vitro testing of Nuvec(R) loaded with two generic siRNA probes, GFP (Green Fluorescent protein) and EHMT-2 (Euchromatic Histone Lysine Methyltransferase 2 ) at the same time. The siRNA probes were loaded onto Nuvec(R) in equal amounts, at a concentration previously shown to be active. Testing demonstrated that both siRNA probes when loaded onto Nuvec(R) were able to significantly silence their respective targets. Nigel Theobald, Chief Executive Officer of the Company, commented : "Showing that Nuvec(R) loaded with two generic siRNA probes still achieves significant silencing of their respective genes is validation for us to now begin the further work that we announced on 14 September with EGFR and BCl-2 in a PC9 lung cancer model. "Achieving the initial successful testing of Nuvec (R) with the generic GFP and EHMT-2 siRNA will also allow us to commence commercial outreach discussions which will only be further strengthened by the results from the new work we are undertaking ." |
Posted at 14/6/2022 12:10 by ch1rp ? If you think that then get out the share. |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
|
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions Support: +44 (0) 203 8794 460 | support@advfn.com |
| ADVFN UK Investors Hub ADVFN Italy ADVFN Australia ADVFN Brazil |
| ADVFN Canada ADVFN Germany ADVFN Japan ADVFN Mexico |
| ADVFN France ADVFN US ADVFN Korea |
